HC Wainwright Has Negative Forecast for Humacyte Q3 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for Humacyte in a research report issued on Thursday, August 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at ($0.07) EPS, FY2029 earnings at $0.09 EPS and FY2030 earnings at $0.31 EPS.

Several other research analysts have also issued reports on the company. Benchmark lowered their target price on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. BTIG Research reissued a “buy” rating and issued a $2.00 price target on shares of Humacyte in a research note on Wednesday, August 12th. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th. Finally, Wall Street Zen downgraded Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Humacyte presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.11.

Humacyte Price Performance

HUMA stock opened at $0.56 on Monday. The company has a market capitalization of $151.16 million, a P/E ratio of -1.14 and a beta of 2.54. The company has a fifty day moving average price of $0.76 and a 200-day moving average price of $0.90. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. Humacyte has a 52-week low of $0.53 and a 52-week high of $2.55.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%.The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC increased its stake in Humacyte by 50.3% in the fourth quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock valued at $33,000 after purchasing an additional 11,411 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of Humacyte during the 2nd quarter worth about $28,000. Price T Rowe Associates Inc. MD boosted its position in shares of Humacyte by 21.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock worth $73,000 after purchasing an additional 13,175 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Humacyte by 41.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock valued at $96,000 after buying an additional 13,407 shares during the period. Finally, Financial Advisors Network Inc. acquired a new stake in shares of Humacyte in the 2nd quarter valued at about $28,000. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.